IMVT - Immunovant, Inc.

QQQ $ 611.58 $ 0.00 (0 %)

DIA $ 467.18 $ 0.00 (0 %)

SPY $ 671.43 $ 0.00 (0 %)

TLT $ 91.59 $ 0.00 (0 %)

GLD $ 391.55 $ 0.00 (0 %)

Previous Close

$ 19.22

Open

$ 17.74

Bid

$ 19.30 x 902

Ask

$ 19.40 x 10

Day's Range

-- - --

52 Week Range

$ 12.72 - $ 32.10

Volume

2,714,076

Average Volume

Market Cap

3.35B

Beta (5Y Monthly)

$ 0.90

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-11-2025	06-30-2025	10-Q
2	05-29-2025	03-31-2025	10-K
3	02-06-2025	12-31-2024	10-Q
4	11-07-2024	09-30-2024	10-Q
5	08-06-2024	06-30-2024	10-Q
6	05-29-2024	03-31-2024	10-K
7	02-12-2024	12-31-2023	10-Q
8	11-09-2023	09-30-2023	10-Q
9	08-10-2023	06-30-2023	10-Q
10	05-22-2023	03-31-2023	10-K
11	02-03-2023	12-31-2022	10-Q
12	11-04-2022	09-30-2022	10-Q
13	08-05-2022	06-30-2022	10-Q
14	06-08-2022	03-31-2022	10-K
15	02-04-2022	12-31-2021	10-Q
16	11-05-2021	09-30-2021	10-Q
17	08-09-2021	06-30-2021	10-Q
18	06-01-2021	03-31-2021	10-K
19	02-16-2021	12-31-2020	10-Q
20	11-12-2020	09-30-2020	10-Q
21	08-12-2020	06-30-2020	10-Q
22	06-29-2020	03-31-2020	10-K
23	02-14-2020	12-31-2019	10-Q
24	11-13-2019	09-30-2019	10-Q
25	08-12-2019	06-30-2019	10-Q
26	06-12-2019	03-31-2019	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Truist Securities Initiates Coverage On Im...
10/14/2025 13:11:00

Truist Securities analyst Danielle Brill initiates coverage on Immunovant (NASDAQ:IMVT) with a Hold rating and announces Pri...

JP Morgan Maintains Overweight on Immunova...
09/30/2025 12:29:23

JP Morgan analyst Brian Cheng maintains Immunovant (NASDAQ:IMVT) with a Overweight and lowers the price target from $37 to $33.

HC Wainwright & Co. Reiterates Buy on Immu...
09/04/2025 10:39:09

HC Wainwright & Co. analyst Douglas Tsao reiterates Immunovant (NASDAQ:IMVT) with a Buy and maintains $35 price target.

Immunovant Reports Durability And Treatmen...
09/03/2025 17:00:43

First-ever potentially disease-modifying therapy for uncontrolled Graves' disease patientsOf 21 patients who entered the si...

JP Morgan Maintains Overweight on Immunova...
08/12/2025 15:44:49

JP Morgan analyst Brian Cheng maintains Immunovant (NASDAQ:IMVT) with a Overweight and lowers the price target from $40 to $37.

B of A Securities Maintains Buy on Immunov...
08/12/2025 12:00:51

B of A Securities analyst Jason Gerberry maintains Immunovant (NASDAQ:IMVT) with a Buy and lowers the price target from $33 ...

Immunovant Q1 EPS $(0.71), Inline
08/11/2025 11:13:55

Immunovant (NASDAQ:IMVT) reported quarterly losses of $(0.71) per share which met the analyst consensus estimate. This is a 18....

UBS Maintains Neutral on Immunovant, Raise...
07/28/2025 22:18:14

UBS analyst Ashwani Verma maintains Immunovant (NASDAQ:IMVT) with a Neutral and raises the price target from $17 to $18.

Immunovant Q4 EPS $(0.64) Beats $(0.73) Es...
05/29/2025 11:09:30

Immunovant (NASDAQ:IMVT) reported quarterly losses of $(0.64) per share which beat the analyst consensus estimate of $(0.73) by...

charles-schwab-to-rally-around-24-here-are-10-top-analyst-forecasts-for-tuesday

Charles Schwab To Rally Around 24%? Here A...
04/22/2025 13:37:04

UBS Downgrades Immunovant to Neutral, Lowe...
04/22/2025 11:58:38

UBS analyst Colin Bristow downgrades Immunovant (NASDAQ:IMVT) from Buy to Neutral and lowers the price target from $38 to $17.

Immunovant Appoints Eric Venker (Currently...
04/21/2025 11:25:28

Guggenheim Reiterates Buy on Immunovantto Buy
03/20/2025 13:47:20

Guggenheim analyst Yatin Suneja reiterates Immunovant (NASDAQ:IMVT) from Buy to Buy.

B of A Securities Maintains Buy on Immunov...
03/20/2025 10:32:24

B of A Securities analyst Jason Gerberry maintains Immunovant (NASDAQ:IMVT) with a Buy and lowers the price target from $38 ...

immunovant-ditches-seeking-fda-approval-for-batoclimab-for-two-autoimmune-disorders-despite-positive-phase-3-data

Immunovant Ditches Seeking FDA Approval Fo...
03/19/2025 16:39:00

Immunovant's batoclimab showed positive Phase 3 results in MG but won't be pursued for approval as the company shifts f...

HC Wainwright & Co. Reiterates Buy on Immu...
03/19/2025 16:33:54

HC Wainwright & Co. analyst Douglas Tsao reiterates Immunovant (NASDAQ:IMVT) with a Buy and maintains $51 price target.

12-health-care-stocks-moving-in-wednesdays-pre-market-session

12 Health Care Stocks Moving In Wednesday'...
03/19/2025 12:07:12

Immunovant Reported Topline Results From I...
03/19/2025 11:46:59

Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point im...

Guggenheim Reiterates Buy on Immunovantto Buy
03/10/2025 16:18:47

Guggenheim analyst Yatin Suneja reiterates Immunovant (NASDAQ:IMVT) from Buy to Buy.

Guggenheim Maintains Buy on Immunovant, Lo...
02/10/2025 13:46:34

Guggenheim analyst Yatin Suneja maintains Immunovant (NASDAQ:IMVT) with a Buy and lowers the price target from $46 to $44.